Business
Helix BioPharma Corp. Announces Fiscal Q1 2010 Results
Helix BioPharma Corp. Announces Fiscal Q1 2010 Results
About this update from Helix Biopharma Corp.
[{"type":"text","content":"\n\n\n\nDec. 9, 2009 (Canada NewsWire Group) -- AURORA, Ontario, Dec. 9 /CNW/ -- Consolidated Statements of Operations for the three month period ended October 31 (thousand $, except for per share data) --------------------------------------- 2009 2008 ---- ---- Revenue: Product revenue 903 921 License fees & royalties 117 198--- ---1,020 1,119 Expenses: Cost of sales 418 447 Research and development 2,925 1,641 Operating, general and admin 677 1,060 Sales and marketing 261 250 Amortization of capital assets 98 64 Amortization of intangible assets - 3 Stock-based compensation 160 - Interest income (14) (205) Foreign exchange loss (gain) (42) 150--- ---4,483 3,410 Loss before income taxes (3,463) (2,291) Income taxes 10 30 --- --- Loss for the year (3,473) (2,321) ====== ====== Loss per share:Basic (0.06) (0.05)Diluted (0.06) (0.05) Consolidated Statements of Cash Flows for the three month period ended October 31 (thousand $, except for per share data) --------------------------------------- 2009 2008 ---- ---- Cash provided by (used in): Loss for the year (3,473) (2,321) Items not involving cash: Amortization of capital assets 98 64 Amortization of intangibles - 3 Deferred lease credit (8) - Stock-based compensation 160 - Foreign exchange loss (gain) (42) 150 --- --- (3,265) (2,104) Change in non-cash working capital 917 486 --- --- Operating activities (2,348) (1,618) Financing activities 11,597 9,659 Investing activities (245) (37) Effect of exchange rate changes on cash and cash equivalents 42 (150) --- ---- Cash and cash equivalents: Increase/(decrease) in the year 9,046 7,854 Beginning of the year 14,494 19,057 ------ ------ End of the year 23,540 26,911====== ====== Consolidated Balance Sheets as at --------------------------------- (thousand $) ------------31-Oct 31-Jul 31-Oct 31-Jul2009 2009 2009 2009 ---- ---- ---- ---- Current assets: Current liabilities: Cash and cash equivalents 23,540 14,494 Accounts payable 1,984 1,299 Accounts receivable 1,178 1,053 Accrued liabilities 843 834 Inventory 867 858 Deferred lease credit 25 25 --- --- Prepaid and other 692 1,049 2,852 2,158--- -----26,277 17,454 Non current liabilities 90 98 --- --- Non current assets 2,005 1,865 Total liabilities 2,942 2,256Shareholders' equity 25,340 17,063----- ----- ------ ------ Total liabilities & Total assets 28,282 19,319 Shareholders' Equity 2...